Bogotá, Colombia, October 15, 2020 – Medcolcanna Organics Inc. (“Medcolcanna”, “MCCN” or the “Company”) (NEO: MCCN) (FRA: MO2), announces the filing of its financial and operating results for the three and six months ended June 30, 2020. All dollar values in this news release and the Company’s financial disclosures are in Canadian dollars, unless otherwise stated. 

Key Developments 

  • Medcolcanna completed the quarter with a $0.4 million cash balance, working capital of $379,558, and recognized revenue of $1,192,920 from an earn-in agreement and product sales. MCCN had a net profit of $18,151 for the 3 months ended June 30th, 2020. The Company recorded revenue of $855,008 USD ($1,187,086 CAD) as it sold a working interest (“WI”) in 2 hectares of cultivation property with newly constructed greenhouses to Dona Blanca Limited (“Dona Blanca”), an unlisted Australian corporation with operations in Colombia. 
  • The Company received final approval for commercial production of certain strains of cannabis from its Colombian operations. This allows the Company to grow certain varieties of cannabis for commercial purposes. As at June 30, 2020, the Company recognized $115,789 of biological assets and had approximately 5,681 kg of dry cannabis equivalent on hand. 
  • The Company received approval for domestic sales from the Colombia National Food and Drug Surveillance Institute, which gives Medcolcanna the ability to sell its line of cosmetics and magistral preparations in the Colombian market. 
  • Medcolcanna currently has 5.7 hectares under greenhouse and has expanded its cultivation to include 2 additional hectares outdoors, for a total cultivation of 7.7 hectares. Of this total 7.7 hectares, the economic benefits of 1.4 hectares will be owned by Dona Blanca per the earn-in agreement, leaving Medcolcanna with a net beneficial interest of 6.3 hectares. 
  • Subsequent to the second quarter, MCCN raised total funds of $2.6M CAD. Medcolcanna issued 10,000,000 common shares at a value of $0.08 per share to Greenstein Capital Ltd. (“Greenstein”) for total proceeds of $800,000. Greenstein also subscribed for $800,000 worth of convertible secured debentures. In August 2020, the Company also closed the first tranche of its convertible debenture financing raising approximately $997,000 and announced the upsizing of the offering to a maximum size of $1.25 million. 
  • In September 2020, the Company entered into a joint venture agreement for the development and commercialization of cannabis-based pharmaceutical products with Grupo Curativa SAS (“Curativa”), an interdisciplinary group of physicians and scientists, internationally recognized for their development and commercialization of various carefully researched products with varying ratios of THC, CBD and other cannabinoids across human and veterinary populations. 
  • The Company has also announced that it has received final approval to have the common shares of the Company listed on Neo Exchange Inc. (“NEO”). The Company’s common shares began trading on the NEO at the open of trading on October 14, 2020. The Company also received approval to voluntarily delist its common shares from the TSXV, effective at the close of business on October 13, 2020. 

Financial Results & Balances 

1) The difference in Net income (loss) to Cash generated from (used in) operations is due to non-cash costs incurred during the six months ended June 30, 2020, such as share-based compensation, depreciation, and unrealized gain on fair value of biological assets 

Management Commentary 

Felipe de la Vega, Medcolcanna President and CEO, commented: “We are pleased to report further progress during the Q2 financial reporting period, including the expansion of additional hectares of commercial greenhouses, recognition of a significant amount of revenue from the sale of a working interest to Dona Blanca, a small net income for the 3 months ended June 30th, 2020, and approval for listing on the NEO.” 

Chris Reid, CFO, commented: “We were able to exit the quarter with a working capital balance of $0.4 million, we also raised $2.6M subsequent to quarter end, further increasing the Company’s treasury. We are pleased that the Company was able to break even for the 3 months ended June 30, 2020, with a small net income due to the non-recuring revenue sale of a working interest to Dona Blanca. The Company also received its final approvals for commercial production of cannabis during the quarter and thus was able to begin commercial harvests and record inventory related to those harvests.


Medcolcanna is a Canadian integrated medical cannabis company, whose fully licensed operations are based in Colombia. Led by a proven and successful management team, Medcolcanna has facilities in optimal growing locations which positions the Company to become a global leader in the medical cannabis market. 

Medcolcanna employs state of the art organic agricultural technology and innovative pharmaceutical processes to produce high-quality products. The Company’s scalable production model and network of pharmaceutical partnerships globally ensures that they remain at the forefront of the medical cannabis industry. 

If you would like to receive News Releases via email as soon as they are published, please subscribe here: or write to info@ 

Additional information about Medcolcanna can be found on its web site at www.

Neither the TSX Venture Exchange Inc. nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Investor Relations Contact: 

Chris Reid, CFO 

Carrera 49b # 93-62 

Bogotá, Colombia 


Felipe de la Vega, CEO 

Carrera 49b # 93-62 

Bogotá, Colombia 


Forward-Looking Statements 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. 

Medcolcanna assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. 

October 15 • 2020

We have received final approval to have the common shares of the Company (“Common Shares”) listed on Neo Exchange Inc. (the “NEO Exchange”). Consequently, the Company has also submitted a request to the TSX Venture Exchange (the “TSXV”) to voluntarily delist the Common Shares from the TSXV.